2-Aminopyrimidines as dual adenosine A1/A2A antagonists.

作者: Sarel J. Robinson , Jacobus P. Petzer , Gisella Terre’Blanche , Anél Petzer , Mietha M. van der Walt

DOI: 10.1016/J.EJMECH.2015.09.035

关键词:

摘要: In this study thirteen 2-aminopyrimidine derivatives were synthesised and screened as potential antagonists of adenosine A1 A2A receptors in order to further investigate the structure activity relationships class compounds. 4-(5-Methylfuran-2-yl)-6-[3-(piperidine-1-carbonyl)phenyl]pyrimidin-2-amine (8m) was identified a compound with high affinities for both receptors, an A2AKi value 6.34 nM A1Ki 9.54 nM. The effect selected compounds on viability cultured cells assessed preliminary results indicate low cytotoxicity. In vivo efficacy at illustrated 8k 8m since these attenuated haloperidol-induced catalepsy rats. A molecular docking revealed that interactions between binding site most likely involve Phe168 Asn253, which are similar structurally related receptor antagonists.

参考文章(58)
Fiona Thomson, Parkinson's Disease Neuron. ,vol. 39, pp. 889- 909 ,(2003) , 10.1016/S0896-6273(03)00568-3
Yoshikuni Mizuno, Tomoyoshi Kondo, , Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease Movement Disorders. ,vol. 28, pp. 1138- 1141 ,(2013) , 10.1002/MDS.25418
Peter Jenner, Huw R. Morris, Trevor W. Robbins, Michel Goedert, John Hardy, Yoav Ben-Shlomo, Paul Bolam, David Burn, John V. Hindle, David Brooks, , Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis Journal of Parkinson's disease. ,vol. 3, pp. 1- 11 ,(2013) , 10.3233/JPD-130175
Stewart A Factor, Kenneth Wolski, Daniel M Togasaki, Susan Huyck, Marc Cantillon, TW Ho, Robert A Hauser, Emmanuelle Pourcher, None, Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease Movement Disorders. ,vol. 28, pp. 817- 820 ,(2013) , 10.1002/MDS.25395
Shawn Branum, Kenneth Wells, Sandra Damon, Scott Youells, Xun Li, Mel Osbourne, Keith Demarest, Yuting Tang, Kenneth Rhodes, Paul F. Jackson, Brian C. Shook, Stefanie Rassnick, Daniel Hall, Kenneth C. Rupert, Geoffrey R. Heintzelman, Kristen Hansen, Devraj Chakravarty, James L. Bullington, Robert H. Scannevin, Brian Magliaro, Lori Westover, Karen Carroll, Lisa Lampron, Ronald Russell, Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists Bioorganic & Medicinal Chemistry Letters. ,vol. 20, pp. 2864- 2867 ,(2010) , 10.1016/J.BMCL.2010.03.042
Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa Neuropsychopharmacology. ,vol. 37, pp. 213- 246 ,(2012) , 10.1038/NPP.2011.212
Anthony H V Schapira, C Warren Olanow, J Timothy Greenamyre, Erwan Bezard, Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. The Lancet. ,vol. 384, pp. 545- 555 ,(2014) , 10.1016/S0140-6736(14)61010-2
Koji Yamada, Minoru Kobayashi, Akihisa Mori, Peter Jenner, Tomoyuki Kanda, Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents Pharmacology, Biochemistry and Behavior. pp. 23- 30 ,(2013) , 10.1016/J.PBB.2013.10.022
Manuel de Lera Ruiz, Yeon-Hee Lim, Junying Zheng, Adenosine A2A Receptor as a Drug Discovery Target Journal of Medicinal Chemistry. ,vol. 57, pp. 3623- 3650 ,(2014) , 10.1021/JM4011669
Kurt A. Jellinger, Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts Movement Disorders. ,vol. 27, pp. 8- 30 ,(2012) , 10.1002/MDS.23795